Insulin lispro Sanofi

Human medicines European public assessment report (EPAR): Neulasta, pegfilgrastim, Date of authorisation: 22/08/2002, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Symkevi, tezacaftor,ivacaftor, Date of authorisation: 31/10/2018, Revision: 17, Status: Authorised

Programme - Joint HMA/EMA multi-stakeholder workshop on Patient Registries December 2025

Medicinal products for human use: monthly figures - November 2025

Human medicines European public assessment report (EPAR): Xermelo, telotristat ethyl, Date of authorisation: 17/09/2017, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Scemblix, asciminib, Date of authorisation: 25/08/2022, Revision: 13, Status: Authorised

Agenda - HMA/EMA Annual Data Forum 2025

Human medicines European public assessment report (EPAR): Filspari, sparsentan, Date of authorisation: 19/04/2024, Revision: 3, Status: Authorised

Committee for Medicinal Products for Human Use (CHMP): 08-11 December 2025, European Medicines Agency, Amsterdam, the Netherlands, from 8 December 2025 to 11 December 2025